Abstract
Biopharmaceutical research and development is sure to dramatically increase
the number of injectable drugs coming to market over the next few years. While
advanced drug delivery techniques continue to hold promise for unique methods
of administration, the traditional injection is still the dominant paradigm.
However, the staggering costs and intransigent safety problems associated with
sharps, along with consumer demand and the move to alternate-site care, are
pushing for alternatives to traditional needles and syringes faster than
advanced delivery technologies can come online.
The alternative in the short term appears to be the growing industry of
needle-free injection and safety-engineered syringes. These devices, ranging
from simple sheathed safety needles to complex gas jet injection systems, are
competing in a vigorous marketplace, some sectors of which are growing at an
annual rate in excess of 20%.
This report analyzes the current world market for needle-free drug delivery
injection systems and safety syringes in terms of dollar volume and unit sales
and makes forecasts through 2009. Regional geographic segmentations are also
provided through the forecast period in both units and dollars. The report
discusses the market's drivers and constraints and provided pertinent data on
the epidemiology of needlestick injuries, the value of injectable drug
markets, and other related issues and trends. It also profiles more than 25
companies involved in marketing or developing these devices, including Antares
Pharma, Becton Dickinson, Bioject, D'Antonio Consultants International,
Retractable Technologies, Safety Syringes Inc., and Tyco Healthcare.
Market forecasts are based on an examination of current market conditions and
on investigations into the development of new products by key companies. The
information presented in this report is the result of data gathered from
company product literature and other corporate brochures and documents, as
well as information found in the scientific and trade press. In addition,
interviews were conducted with company executives, clinicians, researchers and
public health officials.
| 
View Cart
